



#6  
9.6.03  
RECEIVED  
MAY 28 2003  
TECH CENTER 1500/2500

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Philip M. Beart, Ross D. O'Shea, Karina Aprico, Andrew J. Lawrence, and Maria-Luisa Maccicchini

Serial No.: 09/944,954

Art Unit: 1614

Filed: September 1, 2001

Examiner: Not Yet Assigned

For: SCREEN FOR GLUTAMATE REUPTAKE INHIBITORS, STIMULATORS, AND MODULATORS

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including five (5) pages of Form PTO-1449 and copies of forty-five (45) documents cited therein, and a copy of the International Search Report mailed June 13, 2002 in PCT/US01/27323, which corresponds to the above-identified application.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

**BEST AVAILABLE COPY**

### U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
5,658,782	08-19-1997	Amara et al.	435/365
5,731,348	03-24-1998	Gu	514/561
5,739,284	04-14-1998	Hediger et al.	530/350
5,776,774	07-07-1998	Amara et al.	435/325
5,840,516	11-24-1998	Amara et al.	435/29
5,882,926	03-16-1999	Amara et al.	435/325
5,912,171	06-15-1999	Amara et al.	435/325
5,919,699	07-06-1999	Amara et al.	435/325
5,919,628	07-06-1999	Amara et al.	435/6
5,932,424	08-03-1999	Amara et al.	435/6
5,989,825	11-23-1999	Amara et al.	435/6
6,020,479	02-01-2000	Amara et al.	536/23.5
6,060,307	05-09-2000	Amara et al.	435/317.1
6,074,828	06-13-2000	Amara et al.	435/6
6,090,560	07-18-2000	Amara et al.	435/6
6,100,085	08-08-2000	Amara et al.	435/317.1

### Publications

APRICO, et al., "[<sup>3</sup>H]-(2S,4R)-4-methylglutamate: a novel ligand for the characterisation of astrocytic glutamate transporters," *Soc. Neurol. Abstr.* 26(1-2): 539.8 (2000), abstract only.

ARRIZA, et al., "Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance," *Proc. Natl. Acad. Sci. U.S.A.* 94(8): 4155-4160 (1997).

ARRIZA, et al., "Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex," *J. Neurosci.* 14(9): 5559-5569 (1994).

BERGLES & JAHR, "Glial contribution to glutamate uptake at Schaffer collateral-commissural synapses in the hippocampus," *J. Neurosci.* 18(19): 7709-7716 (1998).

BRIDGES, et al., "A pharmacological review of competitive inhibitors and substrates of high-affinity, sodium-dependent glutamate transport in the central nervous system," *Curr. Pharmaceut. Des.* 5(5): 363-379 (1999).

CARROLL, et al., "Regional distribution of low affinity kainate receptors in brain of *Macaca fascicularis* determined by autoradiography using [<sup>3</sup>H](2S,4R)-4-methylglutamate," *Neurosci. Lett.* 255(2): 71-74 (1998).

DUNLOP, et al., "The pharmacological profile of L-glutamate transport in human NT2 neurones is consistent with excitatory amino acid transporter 2," *Eur. J. Pharmacol.* 360(2-3): 249-256 (1998).

DUNLOP, et al., "Properties of excitatory amino acid transport in the human U373 astrocytoma cell line," *Brain Res.* 839(2): 235-242 (1999).

FAIRMAN, et al., "An excitatory amino-acid transporter with properties of a ligand-gated chloride channel," *Nature* 375(6532): 599-603 (1995).

FURUTA, et al., "Glutamate transporter protein subtypes are expressed differentially during rat CNS development," *J. Neurosci.* 17(21): 8363-8375 (1997).

GEGELASHVILI, et al., "High affinity glutamate transporters: regulation of expression and activity," *Mol Pharmacol* 52(1): 6-15 (1997).

GU, et al., "Synthesis, resolution, and biological evaluation of the four stereoisomers of 4-methylglutamic acid: selective probes of kainate receptors," *J Med Chem* 38(14): 2518-2520 (1995).

KANAI, et al., "Primary structure and functional characterization of a high-affinity glutamate transporter," *Nature* 360(6403): 467-471 (1992).

LEBRUN, et al., "New beta-hydroxyaspartate derivatives are competitive blockers for the bovine glutamate/aspartate transporter," *J. Biol. Chem.* 272(33): 20336-20339 (1997).

LI, et al., "The Na<sup>+</sup>-dependent binding of [3H]L-aspartate in thaw-mounted sections of rat forebrain," *Exp. Brain Res.* 97(3): 415-422 (1994).

LIPTON, et al., "Excitatory amino acids as a final common pathway for neurologic disorders," *N. Engl. J. Med.* 330(9): 613-622 (1994).

MITROVIC, et al., "Identification of functional domains of the human glutamate transporters EAAT1 and EAAT2," *J. Biol. Chem.* 273(24): 14698-14706 (1998).

PALOS, et al., "Rat C6 and human astrocytic tumor cells express a neuronal type of glutamate transporter," *Brain Res. Mol. Brain Res.* 37(1-2): 297-303 (1996).

PINES, et al., "Cloning and expression of a rat brain L-glutamate transporter," *Nature* 360(6403): 464-467 (1992).

ROBINSON, et al., "Heterogeneity and functional properties of subtypes of sodium-dependent glutamate transporters in the mammalian central nervous system," *Adv. Pharmacol* 37: 69-115 (1997).

ROTHSTEIN, et al., "Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate," *Neuron* 16(3): 675-686 (1996).

SHIMAMOTO, et al., "DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters," *Mol. Pharmacol.* 53(2): 195-201 (1998).

STORCK, et al., "Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain," *Proc. Natl. Sci. U.S.A.* 89(22): 10955-10959 (1992).

TOMS, et al., "A novel kainate receptor ligand [3H]-(2S,4R)-4-methylglutamate: pharmacological characterization in rabbit brain membranes," *Neuropharmacology* 36(11-12): 1483-1488 (1997).

VANDENBERG, "Molecular pharmacology and physiology of glutamate transporters in the central nervous system," *Clin. Exp. Pharmacol. Physiol.* 25(6): 393-400 (1998).

VANDENBERG, et al., "Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2," *Mol. Pharmacol.* 51(5): 809-815 (1997).

VANDENBERG, et al., "Serine-O-sulphate transport by the human glutamate transporter, EAAT2," *Br. J. Pharmacol.* 123(8): 1593-1600 (1998).

YE, et al., "Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange," *J. Neurosci.* 19(24): 10767-10777 (1999).

ZHOU, et al., "(2S,4R)-4-methylglutamic acid (SYM 2081): a selective, high-affinity ligand for kainate receptors" *J. Pharmacology Exper. Therapeutics* 280(1): 422-427 (1997).

U.S.S.N.: 09/944,954  
Filed: September 01, 2001  
INFORMATION DISCLOSURE STATEMENT




RECEIVED  
MAY 28 2003  
TECH CENTER 1600/2900

**Remarks**

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

  
\_\_\_\_\_  
Patrea L. Pabst  
Reg. No. 31,284

Dated: May 23, 2003

HOLLAND & KNIGHT LLP  
One Atlantic Center  
1201 West Peachtree Street, N.E.  
Suite 2000  
Atlanta, Georgia 30309-3400  
404-817-8473  
FAX 404-817-8588  
www.hklaw.com

U.S.S.N.: 09/944,954  
Filed: September 01, 2001  
INFORMATION DISCLOSURE STATEMENT




RECEIVED  
MAY 28 2003  
TECH CENTER 1600/2900

**Certificate of Mailing under 37 C.F.R. § 1.8(a)**

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Commissioner for Patents, Alexandria, VA 22313.

Date: May 22, 2003

  
Aisha Wyatt

ATL1 #526547 v1

Please type a plus sign (+) inside this box →



PTO/SB08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Applicant Number	09/944,954
Filing Date	September 1, 2001
First Named Inventor	Phillip M. Beart
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	SYM 116/118

Sheet	1	of	5
-------	---	----	---

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		5,658,782		Amara et al.	08-19-1997	
		5,731,348		Gu	03-24-1998	
		5,739,284		Hediger et al.	04-14-1998	
		5,776,774		Amara et al.	07-07-1998	
		5,840,516		Amara et al.	11-24-1998	
		5,882,926		Amara et al.	03-16-1999	
		5,912,171		Amara et al.	06-15-1999	
		5,919,699		Amara et al.	07-06-1999	
		5,919,628		Amara et al.	07-06-1999	
		5,932,424		Amara et al.	08-03-1999	
		5,989,825		Amara et al.	11-23-1999	
		6,020,479		Amara et al.	02-01-2000	
		6,060,307		Amara et al.	05-09-2000	
		6,074,828		Amara et al.	06-13-2000	
		6,090,560		Amara et al.	07-18-2000	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office. <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

Examine Signature		Date Considered	
-------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.


<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.





Please type a plus sign (+) inside this box →



Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information on this form unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				Completeness	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Applicant Number	09/944,954
				Filing Date	September 1, 2001
				First Named Inventor	Phillip M. Beart
				Group Art Unit	1614
				Examiner Name	
Sheet	5	of	5	Attorney Docket Number	SYM 116/118

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	✓	ROTHSTEIN, et al., "Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate," <i>Neuron</i> 16(3): 675-686 (1996).	
	✓	SHIMAMOTO, et al., "DL-threo-beta-benzoyloxyaspartate, a potent blocker of excitatory amino acid transporters," <i>Mol. Pharmacol.</i> 53(2): 195-201 (1998).	
	✓	STORCK, et al., "Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain," <i>Proc. Natl. Sci. U.S.A.</i> 89(22): 10955-10959 (1992).	
	✓	TOMS, et al., "A novel kainate receptor ligand [3H]-(2S,4R)-4-methylglutamate: pharmacological characterization in rabbit brain membranes," <i>Neuropharmacology</i> 36(11-12): 1483-1488 (1997).	
	✓	VANDENBERG, "Molecular pharmacology and physiology of glutamate transporters in the central nervous system," <i>Clin. Exp. Pharmacol. Physiol.</i> 25(6): 393-400 (1998).	
	✓	VANDENBERG, et al., "Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2," <i>Mol. Pharmacol.</i> 51(5): 809-815 (1997).	
	✓	VANDENBERG, et al., "Serine-O-sulphate transport by the human glutamate transporter, EAAT2," <i>Br. J. Pharmacol.</i> 123(8): 1593-1600 (1998).	
	✓	YE, et al., "Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange," <i>J. Neurosci.</i> 19(24): 10767-10777 (1999).	
	✓	ZHOU, et al., "(2S,4R)-4-methylglutamic acid (SYM 2081): a selective, high-affinity ligand for kainate receptors" <i>J. Pharmacology Exper. Therapeutics</i> 280(1): 422-427 (1997).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



RECEIVED  
MA 8 2003  
TECH CENTER 1600/2900

PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Compleat If Kn wn	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Applicati n Number	09/944,954
				Filing Date	September 1, 2001
				First Named Inventor	Phillip M. Beart
				Group Art Unit	1614
				Examiner Name	
Sheet	3	of	5	Attorney Docket Number	SYM 116/118

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	✓	APRICO, et al., "[ <sup>3</sup> H]- (2S,4R)-4-methylglutamate: a novel ligand for the characterisation of astrocytic glutamate transporters," <i>Soc. Neurol. Abstr.</i> 26(1-2): 539.8 (2000), abstract only.	
	✓	ARRIZA, et al., "Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 94(8): 4155-4160 (1997).	
	✓	ARRIZA, et al., "Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex," <i>J. Neurosci.</i> 14(9): 5559-5569 (1994).	
	✓	BERGLES & JAHR, "Glial contribution to glutamate uptake at Schaffer collateral-commissural synapses in the hippocampus," <i>J. Neurosci.</i> 18(19): 7709-7716 (1998).	
	✓	BRIDGES, et al., "A pharmacological review of competitive inhibitors and substrates of high-affinity, sodium-dependent glutamate transport in the central nervous system," <i>Curr. Pharmaceut. Des.</i> 5(5): 363-379 (1999).	
	✓	CARROLL, et al., "Regional distribution of low affinity kainate receptors in brain of Macaca fascicularis determined by autoradiography using [ <sup>3</sup> H](2S,4R)-4-methylglutamate," <i>Neurosci. Lett.</i> 255(2): 71-74 (1998).	
	✓	DUNLOP, et al., "The pharmacological profile of L-glutamate transport in human NT2 neurones is consistent with excitatory amino acid transporter 2," <i>Eur. J. Pharmacol.</i> 360(2-3): 249-256 (1998).	
	✓	DUNLOP, et al., "Properties of excitatory amino acid transport in the human U373 astrocytoma cell line," <i>Brain Res.</i> 839(2): 235-242 (1999).	
	✓	FAIRMAN, et al., "An excitatory amino-acid transporter with properties of a ligand-gated chloride channel," <i>Nature</i> 375(6532): 599-603 (1995).	
	✓	FURUTA, et al., "Glutamate transporter protein subtypes are expressed differentially during rat CNS development," <i>J. Neurosci.</i> 17(21): 8363-8375 (1997).	


Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



Y 2 8 2003  
TECH CENTER 1600/2900

PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it carries a valid OMB control number

Substitute for form 1449A/PTO				Compl t If Kn wn	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Applicati n Number	09/944,954
				Filing Date	September 1, 2001
				First Named Inventor	Phillip M. Beart
				Group Art Unit	1614
				Examiner Name	
Sheet	4	of	5	Attorney Docket Number	SYM 116/118

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	/	GEDELASHVILI, et al., "High affinity glutamate transporters: regulation of expression and activity," <i>Mol Pharmacol</i> 52(1): 6-15 (1997).	
	/	GU, et al., "Synthesis, resolution, and biological evaluation of the four stereoisomers of 4-methylglutamic acid: selective probes of kainate receptors," <i>J Med Chem</i> 38(14): 2518-2520 (1995).	
	/	KANAI, et al., "Primary structure and functional characterization of a high-affinity glutamate transporter," <i>Nature</i> 360(6403): 467-471 (1992).	
	/	LEBRUN, et al., "New beta-hydroxyaspartate derivatives are competitive blockers for the bovine glutamate/aspartate transporter," <i>J. Biol. Chem.</i> 272(33): 20336-20339 (1997).	
	/	LI, et al., "The Na <sup>+</sup> -dependent binding of [3H]-L-aspartate in thaw-mounted sections of rat forebrain," <i>Exp. Brain Res.</i> 97(3): 415-422 (1994).	
	/	LIPTON, et al., "Excitatory amino acids as a final common pathway for neurologic disorders," <i>N. Engl. J. Med.</i> 330(9): 613-622 (1994).	
	/	MITROVIC, et al., "Identification of functional domains of the human glutamate transporters EAAT1 and EAAT2," <i>J. Biol. Chem.</i> 273(24): 14698-14706 (1998).	
	/	PALOS, et al., "Rat C6 and human astrocytic tumor cells express a neuronal type of glutamate transporter," <i>Brain Res. Mol. Brain Res.</i> 37(1-2): 297-303 (1996).	
	/	PINES, et al., "Cloning and expression of a rat brain L-glutamate transporter," <i>Nature</i> 360(6403): 464-467 (1992).	
	/	ROBINSON, et al., "Heterogeneity and functional properties of subtypes of sodium-dependent glutamate transporters in the mammalian central nervous system," <i>Adv. Pharmacol</i> 37: 69-115 (1997).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.